Scott, Lesley J. Dulaglutide: a review in type 2 diabetes <p><b>Compliance with Ethical Standards</b></p> <p><b>Funding</b> The preparation of this review was not supported by any external funding.</p> <p><b>Conflicts of interest</b><b><i> </i></b>Lesley Scott is a salaried employee of Adis International Ltd/Springer Nature, is responsible for the article content and declares no relevant conflicts of interest.</p><p><br></p><p>Additional information about this Adis Drug Review can be found here</p><p><b><br></b></p><p><b>Abstract</b><br></p><p> Subcutaneous dulaglutide is a once-weekly glucagon-like peptide-1 receptor agonist that is approved in numerous countries as an adjunct to diet and exercise for the treatment of adults with type 2 diabetes (T2D). In the clinical trial and real-world settings, once-weekly subcutaneous dulaglutide, as monotherapy or add-on therapy to other antihyperglycaemic drugs (including oral antihyperglycaemic drugs and insulin), was an effective and generally well tolerated treatment in adults with inadequately controlled T2D, including in high-risk patients [e.g. obese and elderly patients, those with stage 3 or 4 chronic kidney disease (CKD) and/or cardiovascular (CV) disease]. In the REWIND CV outcomes trial in patients with T2D with or without CV disease, dulaglutide was associated with a significant reduction in the risk of a major adverse cardiac event (MACE; primary composite outcome comprising CV death, nonfatal myocardial infarction or nonfatal stroke) at a median of 5.4 years’ follow-up. Given its durable glycaemic efficacy, beneficial effects on bodyweight and MACE outcomes, low inherent risk of hypoglycaemia and convenient once-weekly regimen, dulaglutide remains an important option in the management of T2D.<br></p><p><br></p><p></p><p>© Springer Nature Switzerland AG 2020</p><p><br></p><p><br></p> dulaglutide;type 2 diabetes\;review;Adis Drug Evaluation 2020-02-02
    https://adisjournals.figshare.com/articles/online_resource/Dulaglutide_a_review_in_type_2_diabetes/11356868
10.6084/m9.figshare.11356868.v1